This is a phase II trial evaluating the safety and efficacy of the combination of Ibrutinib
and Rituximab as primary treatment of chronic GVHD. We plan to enroll 35 patients on this
study. Patients will be formally monitored monthly for 12 months to evaluate for outcome and
safety endpoints. All other assessments will be done at the physician's discretion or
institutional standards. All patients, responders and treatment failures, will be followed
for a period of one year from the time of initiation of therapy. The primary endpoint will be
the proportion of patients that are alive and off all systemic IST at 12 months following
initiation of treatment.